AstraZeneca's COVID-19 vaccine Vaxzevria is no longer available in New Zealand - it is now expired (5 September). The second line vaccine is Nuvaxovid from Novavax.

Vaxzevria is a vaccine that protects against COVID-19 disease caused by the SARS-CoV-2 virus.

Name: COVID-19 AstraZeneca Vaccine 
Alternative brand name: Vaxzevria®
Manufacturer: AstraZeneca
Type of vaccine: Viral vector vaccine
Number of doses: For use from 18 years of age
Two doses given intramuscularly from 4 – 12 weeks apart
New Zealand availability: The AstraZeneca COVID-19 vaccine is available for those aged 18 years and older, who cannot receive the Pfizer vaccine, and for those who would prefer a different option.

Pfizer remains the preferred COVID-19 vaccine for use in New Zealand. 

Medsafe datasheet and consumer information sheet 

Vaccine comparison chart COVID-19 v1

Immunisation Handbook

References at the end of this page.

General information and resource links for AstraZeneca

This page provides information on AstraZeneca and resources available for use.

Visit page:

How AstraZeneca is made and what it contains

On this page you will find:

  • What type of vaccine is AstraZeneca?
  • What does AstraZeneca contain?
  • How is the AstraZeneca vaccine made?

Visit page: 

How the AstraZeneca vaccine works and the protection it provides

On this page you will find:

  • How does the AstraZeneca vaccine work?
  • How protective is the AstraZeneca vaccine?
  • What is the difference between the Pfizer COVID-19 vaccine and the AstraZeneca COVID-19 vaccine?
  • How effective is the AstraZeneca vaccine against the Delta variant?
  • How long does protection last?
  • Will the AstraZeneca vaccine cause a positive COVID-19 test?

Visit page:

AstraZeneca vaccine and responses in pregnant/breastfeeding women:

  • Can pregnant women receive the AstraZeneca vaccine?
  • Can breastfeeding women receive the AstraZeneca vaccine?

Visit page:

Potential Vaccine Responses:

Visit page:


Agrawal U, Katikireddi SV, McCowan C, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med, Sep 2021 

Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv, Sep 2021 (preprint): p. 2021.09.15.21263583

Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. New England Journal of Medicine, Sep 2021

Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, Sep 2021. 398(10304): p. 981-990

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. May 2021; 373:1088

Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021. 285(7): p. 585.594

Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infectious Diseases, April 2021

Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, Nov 2020. 396(10267): p. 1979-1993

Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. New England Journal of Medicine, April 2021

Stowe J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. July 2021 (pre print)

Ura T, Okuda K, Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines. Sep 2014;2(3):624-641

Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet, April 2021. 397(10285): p. 1646-1657

Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, Jan 2021. 397(10269): p. 99-111

World Health Organisation [Internet]: The different types of COVID-19 vaccines. Who int. 2021. Available from:

Last updated: 05 September 2022